Home page > Women’s Health

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data

Women's health refers to the health of women, which differs from that of men in many unique ways. Women's health is defined by the World Health Organization as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity". Often treated as simply women's reproductive health and in terms of diseases that appear in the female reproductive organs 




Number of years ago in 1960, a week synthetic estrogen was developed as an anti-infertility drug. This was TRIPARA -ANISYLCHLORO- ETHYLENE. A derivative of this drug was CLOMIPHENE CITRATE - an effective ovulatory drug in humans. Clomiphene citrate has been the most widely used treatment for fertility enhancement for the past 35 years.

Prolifen (Clomiphene Citrate) Acts As A Competitive Inhibitor Of Estrogen, Blocking Estrogen At The Hypothalamic Level, Thus Removing The Inhibition To Pituitary Gonadotropin Production And Allowing A Gonadotrophic Flood. The Increased Gonadotropin Secretion Causes Excessive Ovarian Stimulation, with Excretion of Urinary Estrogen, Ovulation and Normal Corpusluteum Function


Dosage and Administration

The recommended dose for first treatment cycle with PROLIFEN is 50 mg (1 capsule) daily for 5 days. When ovulation occurs at this dosage there is no advantage in increasing the dose in subsequent cycles of treatment.

If ovulation occurs at this dosage but is not followed by pregnancy, subsequent courses for a total maximum of 6 cycles of PROLIFEN treatment may be administered. If ovulation does not occur after first course of therapy a second course of 100 mg daily (two 50 mg capsules given as two daily doses) for five days should be given. If ovulatory menses do not occur, this dose may be repeated for two additional cycles, but failure to induce ovulation after 3 consecutive cycles at this dosage should constitute an adequate therapeutic trial. The importance of properly timed coitus should be over-emphasized. Therapy may be started at any time in a patient who has had no recent uterine bleeding, but if progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs prior to therapy, the cycle with PROLIFEN should be started on or about the fifth day of the cycle.